Glutavista Injection, containing L-alanyl-L-glutamine at a concentration of 20% w/v, is an amino acid dipeptide solution designed for intravenous administration. It serves as a vital nutritional supplement, providing a stable and readily bioavailable source of glutamine, an essential amino acid involved in numerous metabolic processes including nitrogen transport, immune function, and intestinal health. Glutavista Injection is indicated for patients requiring parenteral nutrition support, particularly those with compromised glutamine levels due to critical illness, trauma, surgery, or malnutrition. The dipeptide form enhances solubility and stability compared to free glutamine, facilitating effective delivery and utilization. This formulation supports protein synthesis, promotes tissue repair, and aids in maintaining gut mucosal integrity, thereby reducing the risk of bacterial translocation and infection. Administration should be performed under medical supervision, with dosage tailored according to individual patient needs and clinical condition. Glutavista Injection is contraindicated in patients with known hypersensitivity to its components. Caution is advised in patients with hepatic or renal impairment. Adverse effects are rare but may include local irritation or allergic reactions. Proper aseptic technique is essential during preparation and administration to prevent contamination. Glutavista Injection is a valuable adjunct in comprehensive nutritional therapy for critically ill patients requiring enhanced amino acid support.